The Company reaffirms previously provided preliminary financial results for the quarter and full year ended December 31, 2024, and continues to expect regulatory decisions on DrugSorbâ„¢-ATR marketing applications in 2025 PRINCETON, N.J., March 21, 2025 /PRNewswire/ — CytoSorbents…